323 related articles for article (PubMed ID: 29108938)
1. Fractional exhaled nitric oxide as a predictor of response to inhaled corticosteroids in patients with non-specific respiratory symptoms and insignificant bronchodilator reversibility: a randomised controlled trial.
Price DB; Buhl R; Chan A; Freeman D; Gardener E; Godley C; Gruffydd-Jones K; McGarvey L; Ohta K; Ryan D; Syk J; Tan NC; Tan T; Thomas M; Yang S; Konduru PR; Ngantcha M; d'Alcontres MS; Lapperre TS
Lancet Respir Med; 2018 Jan; 6(1):29-39. PubMed ID: 29108938
[TBL] [Abstract][Full Text] [Related]
2. Use of beclomethasone dipropionate as rescue treatment for children with mild persistent asthma (TREXA): a randomised, double-blind, placebo-controlled trial.
Martinez FD; Chinchilli VM; Morgan WJ; Boehmer SJ; Lemanske RF; Mauger DT; Strunk RC; Szefler SJ; Zeiger RS; Bacharier LB; Bade E; Covar RA; Friedman NJ; Guilbert TW; Heidarian-Raissy H; Kelly HW; Malka-Rais J; Mellon MH; Sorkness CA; Taussig L
Lancet; 2011 Feb; 377(9766):650-7. PubMed ID: 21324520
[TBL] [Abstract][Full Text] [Related]
3. Dose-response relationship and reproducibility of the fall in exhaled nitric oxide after inhaled beclomethasone dipropionate therapy in asthma patients.
Silkoff PE; McClean P; Spino M; Erlich L; Slutsky AS; Zamel N
Chest; 2001 May; 119(5):1322-8. PubMed ID: 11348935
[TBL] [Abstract][Full Text] [Related]
4. Effect of montelukast added to inhaled corticosteroids on fractional exhaled nitric oxide in asthmatic children.
Ghiro L; Zanconato S; Rampon O; Piovan V; Pasquale MF; Baraldi E
Eur Respir J; 2002 Sep; 20(3):630-4. PubMed ID: 12358339
[TBL] [Abstract][Full Text] [Related]
5. Inhaled corticosteroid dose response using domiciliary exhaled nitric oxide in persistent asthma: the FENOtype trial.
Anderson WJ; Short PM; Williamson PA; Lipworth BJ
Chest; 2012 Dec; 142(6):1553-1561. PubMed ID: 23364390
[TBL] [Abstract][Full Text] [Related]
6. Rapid effects of extrafine beclomethasone dipropionate/formoterol fixed combination inhaler on airway inflammation and bronchoconstriction in asthma: a randomised controlled trial.
O'Connor BJ; Collarini S; Poli G; Brindicci C; Spinola M; Acerbi D; Barnes PJ; Leaker B
BMC Pulm Med; 2011 Dec; 11():60. PubMed ID: 22188731
[TBL] [Abstract][Full Text] [Related]
7. Benralizumab for patients with mild to moderate, persistent asthma (BISE): a randomised, double-blind, placebo-controlled, phase 3 trial.
Ferguson GT; FitzGerald JM; Bleecker ER; Laviolette M; Bernstein D; LaForce C; Mansfield L; Barker P; Wu Y; Jison M; Goldman M;
Lancet Respir Med; 2017 Jul; 5(7):568-576. PubMed ID: 28545978
[TBL] [Abstract][Full Text] [Related]
8. Beclometasone-formoterol as maintenance and reliever treatment in patients with asthma: a double-blind, randomised controlled trial.
Papi A; Corradi M; Pigeon-Francisco C; Baronio R; Siergiejko Z; Petruzzelli S; Fabbri LM; Rabe KF
Lancet Respir Med; 2013 Mar; 1(1):23-31. PubMed ID: 24321801
[TBL] [Abstract][Full Text] [Related]
9. A comparison of 2 extrafine hydrofluoroalkane-134a-beclomethasone formulations on methacholine hyperresponsiveness.
Fardon TC; Burns P; Barnes ML; Lipworth BJ
Ann Allergy Asthma Immunol; 2006 Mar; 96(3):422-30. PubMed ID: 16597076
[TBL] [Abstract][Full Text] [Related]
10. Exhaled nitric oxide in children with asthma receiving Xolair (omalizumab), a monoclonal anti-immunoglobulin E antibody.
Silkoff PE; Romero FA; Gupta N; Townley RG; Milgrom H
Pediatrics; 2004 Apr; 113(4):e308-12. PubMed ID: 15060258
[TBL] [Abstract][Full Text] [Related]
11. Tailored interventions based on exhaled nitric oxide versus clinical symptoms for asthma in children and adults.
Petsky HL; Cates CJ; Li A; Kynaston JA; Turner C; Chang AB
Cochrane Database Syst Rev; 2009 Oct; (4):CD006340. PubMed ID: 19821360
[TBL] [Abstract][Full Text] [Related]
12. Both bronchial and alveolar exhaled nitric oxide are reduced with extrafine beclomethasone dipropionate in asthma.
Nicolini G; Chetta A; Simonazzi A; Tzani P; Aiello M; Olivieri D
Allergy Asthma Proc; 2010; 31(5):85-90. PubMed ID: 20929599
[TBL] [Abstract][Full Text] [Related]
13. The Breathing for Life Trial: a randomised controlled trial of fractional exhaled nitric oxide (FENO)-based management of asthma during pregnancy and its impact on perinatal outcomes and infant and childhood respiratory health.
Murphy VE; Jensen ME; Mattes J; Hensley MJ; Giles WB; Peek MJ; Bisits A; Callaway LK; McCaffery K; Barrett HL; Colditz PB; Seeho SK; Attia J; Searles A; Doran C; Powell H; Gibson PG
BMC Pregnancy Childbirth; 2016 May; 16():111. PubMed ID: 27189595
[TBL] [Abstract][Full Text] [Related]
14. A novel formulation of inhaled sodium cromoglicate (PA101) in idiopathic pulmonary fibrosis and chronic cough: a randomised, double-blind, proof-of-concept, phase 2 trial.
Birring SS; Wijsenbeek MS; Agrawal S; van den Berg JWK; Stone H; Maher TM; Tutuncu A; Morice AH
Lancet Respir Med; 2017 Oct; 5(10):806-815. PubMed ID: 28923239
[TBL] [Abstract][Full Text] [Related]
15. Assessing Inhaled Corticosteroid Adherence and Responsiveness in Severe Asthma Using Beclometasone Dipropionate/Formoterol NEXThaler Dose-Counting and Nitric Oxide Monitoring.
Aung HWW; Boddy CE; Hampson E; Bell M; Parnell LA; Balasundaram K; Murphy AC; Naveed S; Bradding P
J Allergy Clin Immunol Pract; 2024 Jun; 12(6):1539-1546.e5. PubMed ID: 38518866
[TBL] [Abstract][Full Text] [Related]
16. Tralokinumab for severe, uncontrolled asthma (STRATOS 1 and STRATOS 2): two randomised, double-blind, placebo-controlled, phase 3 clinical trials.
Panettieri RA; Sjöbring U; Péterffy A; Wessman P; Bowen K; Piper E; Colice G; Brightling CE
Lancet Respir Med; 2018 Jul; 6(7):511-525. PubMed ID: 29792288
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of AZD7594, an inhaled non-steroidal selective glucocorticoid receptor modulator, in patients with asthma: a phase 2a randomized, double blind, placebo-controlled crossover trial.
Brown MN; Fuhr R; Beier J; Su HL; Chen Y; Forsman H; Hamrén UW; Jackson H; Aggarwal A
Respir Res; 2019 Feb; 20(1):37. PubMed ID: 30777086
[TBL] [Abstract][Full Text] [Related]
18. Exhaled nitric oxide monitoring does not reduce exacerbation frequency or inhaled corticosteroid dose in paediatric asthma: a randomised controlled trial.
Pike K; Selby A; Price S; Warner J; Connett G; Legg J; Lucas JS; Peters S; Buckley H; Magier K; Foote K; Drew K; Morris R; Lancaster N; Roberts G
Clin Respir J; 2013 Apr; 7(2):204-13. PubMed ID: 22747899
[TBL] [Abstract][Full Text] [Related]
19. Composite type-2 biomarker strategy versus a symptom-risk-based algorithm to adjust corticosteroid dose in patients with severe asthma: a multicentre, single-blind, parallel group, randomised controlled trial.
Heaney LG; Busby J; Hanratty CE; Djukanovic R; Woodcock A; Walker SM; Hardman TC; Arron JR; Choy DF; Bradding P; Brightling CE; Chaudhuri R; Cowan DC; Mansur AH; Fowler SJ; Niven RM; Howarth PH; Lordan JL; Menzies-Gow A; Harrison TW; Robinson DS; Holweg CTJ; Matthews JG; Pavord ID;
Lancet Respir Med; 2021 Jan; 9(1):57-68. PubMed ID: 32916135
[TBL] [Abstract][Full Text] [Related]
20. Inhaled JAK inhibitor GDC-0214 reduces exhaled nitric oxide in patients with mild asthma: A randomized, controlled, proof-of-activity trial.
Braithwaite IE; Cai F; Tom JA; Galanter JM; Owen RP; Zhu R; Williams M; McGregor AG; Eliahu A; Durk MR; Dengler HS; Zak M; Kenny JR; Wilson ME; Beasley R; Chen H
J Allergy Clin Immunol; 2021 Sep; 148(3):783-789. PubMed ID: 33744327
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
